NIH Awards Grant for Autofluorescence-Free Cytometry Development
Kinetic River has been awarded a Phase II SBIR grant for the development of an autofluorescence-free flow cytometry platform.
Kinetic River has been awarded a Phase II SBIR grant for the development of an autofluorescence-free flow cytometry platform.
Bluestar Genomics’ technology can noninvasively detect cancers and help identify the underlying biology of the disease using epigenetic markers.
The funds will be used to accelerate commercialization of Saga’s portfolio of kits and services, continue development of new products, and perform prospective clinical studies.
New applications include customizable QIAact target enrichment panels for next-generation sequencing of more than 13 hereditary disease groups.
Read MoreSeraCare Life Sciences has expanded its suite of clinical genomics development, validation, and quality control tools with the launch of Seraseq myeloid DNA and myeloid RNA fusion reference materials.
Read MoreBio-Rad Laboratories has introduced the QXDx BCR-ABL %IS kit, a CE-marked digital polymerase chain reaction test that can monitor the molecular response to therapy of patients with chronic myeloid leukemia.
Read MoreAgency allows marketing of the QuantideX qPCR BCR-ABL IS kit, the first nucleic acid-based quantitation test for use during treatment of rare leukemia.
Read MoreAfter its ASH 2014 debut, the RainDance HemOnc Consortium, an international panel of clinical research experts, will focus on developing assays for liquid biopsy research of myeloid disorders.
Read MoreA new collaboration plans to provide genomic profiling and information for patients that have been unsuccessful on repeated therapy for the group of cancers that include leukemias, lymphomas, and myeloproliferative and myelodysplastic diseases.
Read MoreThe test has been shown to offer sensitivity for the detection of residual cancer cells in marrow or blood.
Read MoreWith so many types of lymphoma, there’s a wide range of corresponding lab tests to detect their presence in patients. Here, CLP takes a look at testing for the most common type of lymphoma (diffuse large B-cell
Read More